[{"orgOrder":0,"company":"Uni-Bio Science","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Peptide, Unconjugated","year":"2025","type":"Partnership","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Uni-Bio Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uni-Bio Science \/ Kexing Biopharm","highestDevelopmentStatusID":"15","companyTruncated":"Uni-Bio Science \/ Kexing Biopharm"}]

Find Clinical Drug Pipeline Developments & Deals by Uni-Bio Science

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Genetech has granted Kexing exclusive rights to commercialize Bogutai (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.

                          Product Name : Bogutai

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          September 12, 2025

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Kexing Biopharm

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank